NASDAQ:AWH - Nasdaq - US04537Y2081 - Common Stock - Currency: USD
0.17
-0.06 (-24.78%)
The current stock price of AWH is 0.17 USD. In the past month the price decreased by -58.55%. In the past year, price decreased by -95.74%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 29.09 | 235.66B | ||
ISRG | INTUITIVE SURGICAL INC | 76.91 | 201.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 40.16 | 148.56B | ||
SYK | STRYKER CORP | 31.9 | 148.26B | ||
MDT | MEDTRONIC PLC | 16.99 | 116.35B | ||
BDX | BECTON DICKINSON AND CO | 16.12 | 64.37B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.25 | 42.11B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 19.91 | 40.84B | ||
IDXX | IDEXX LABORATORIES INC | 39.2 | 36.11B | ||
DXCM | DEXCOM INC | 53.22 | 34.30B | ||
RMD | RESMED INC | 26.16 | 33.97B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.83 | 24.47B |
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 64 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.
ASPIRA WOMEN'S HEALTH INC
12117 Bee Caves Road Building Three, Suite 100
Austin TEXAS 78738 US
CEO: Valerie B. Palmieri
Employees: 64
Company Website: https://aspirawh.com/
Investor Relations: https://ir.aspirawh.com/
Phone: 15125190400
The current stock price of AWH is 0.17 USD. The price decreased by -24.78% in the last trading session.
The exchange symbol of ASPIRA WOMEN'S HEALTH INC is AWH and it is listed on the Nasdaq exchange.
AWH stock is listed on the Nasdaq exchange.
5 analysts have analysed AWH and the average price target is 5.61 USD. This implies a price increase of 3200% is expected in the next year compared to the current price of 0.17. Check the ASPIRA WOMEN'S HEALTH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ASPIRA WOMEN'S HEALTH INC (AWH) has a market capitalization of 2.83M USD. This makes AWH a Nano Cap stock.
ASPIRA WOMEN'S HEALTH INC (AWH) currently has 64 employees.
The Revenue of ASPIRA WOMEN'S HEALTH INC (AWH) is expected to grow by 5.88% in the next year. Check the estimates tab for more information on the AWH EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AWH does not pay a dividend.
ASPIRA WOMEN'S HEALTH INC (AWH) will report earnings on 2025-03-26, after the market close.
ASPIRA WOMEN'S HEALTH INC (AWH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.2).
The outstanding short interest for ASPIRA WOMEN'S HEALTH INC (AWH) is 3.56% of its float. Check the ownership tab for more information on the AWH short interest.
ChartMill assigns a fundamental rating of 2 / 10 to AWH. AWH has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months AWH reported a non-GAAP Earnings per Share(EPS) of -1.2. The EPS increased by 42.58% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -310.88% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to AWH. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 39.63% and a revenue growth 5.88% for AWH